Jul 15, 2026
By Transpire Insight
Description
According to a research report published by Transpire Insight, The Global Pharmaceutical Contract Development and Manufacturing Organization Market Size is projected to Grow from USD 198.00 Billion in 2026 to USD 400.00 Billion by 2035, at a CAGR of 10.55% during the forecast period 2026-2035. Market growth is being fueled by the rising outsourcing trend among pharmaceutical and biotech companies, growing demand for biologics and cell/gene therapy products, growing number of clinical trials, and increased investments in advanced manufacturing technology. Rising adoption of continuous manufacturing, personalized medicines, high-potency active pharmaceutical ingredients, and flexible manufacturing sites is also driving the market growth. In addition, the rising research and development expenditure, patent expiration, and cost-effective manufacturing of drugs are expected to provide ample growth opportunities to the Pharmaceutical CDMO Market during the forecast period.
Introduction
The Pharmaceuticals Contract Development and Manufacturing Organization (CDMO) Market includes companies providing third-party services of developing, manufacturing, formulating, analyzing, packaging, and commercializing drugs for pharmaceutical, biotech, and life sciences firms. CDMOs help drug makers speed up their product development, save costs on investments, increase efficiency in operations, and gain access to unique manufacturing capacities. The rising popularity of outsourcing, the increase in biologicals production, and increasing complexities in drug development are boosting the demand for CDMO services globally.
Recent Development News
Stay Ahead of Emerging Opportunities with Expert Market Insights by Transpire Insight
The insights that have been shared through this blog are based on intensive market research carried out by Transpire Insight, an advisor that works with many global organizations. Thanks to the analysis of extensive data, forecasts made by our specialists, and industry intelligence, our reports allow clients to find strategic growth opportunities in dynamically developing industries. For all those who would like to get more detailed information regarding market segmentation, competitive analysis, regional outlooks, and future investment tendencies, there is no doubt that our full report will be of great value.
Download the exclusive Pharmaceutical CDMO Market sample report today to uncover expert insights, emerging trends, and the opportunities defining the future of the industry.
Pharmaceutical Contract Development and Manufacturing Organization Market Size & Statistics
Regional Growth and Demand Analysis by Transpire Insight:
North America is the most dominant region within the Pharmaceutical CDMO Market, having about 42% of the global market share. This dominance in the market is owed to the existence of many big pharmaceutical and biotechnology companies, developed manufacturing infrastructure, high investments in R&D, and extensive outsourcing of the processes of developing and manufacturing drugs. Moreover, the robust regulatory framework provided by institutions like the FDA in the USA and the rapid adoption of biologics and cell & gene therapies also contribute to the dominance of North America in the CDMO market.
The Asia-Pacific region is projected to grow at the highest rate during the forecasted period owing to its increasing pharmaceutical manufacturing capacity, declining cost of production and labor, increased investments in biologics and biosimilars, and favorable government policies. Countries including China, India, South Korea, Singapore, and Japan are increasingly emerging as major players in the outsourcing business owing to their increasing manufacturing capacities, skilled labor, clinical trials, and demand for efficient pharmaceutical development and manufacturing services.
Top 15 Trends in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
Proceed to Checkout to purchase the exclusive Pharmaceutical CDMO Market report and gain instant access to in-depth market intelligence, strategic analysis, and future growth opportunities.
1. Increasing Outsourcing of Drug Development and Manufacturing
Pharmaceutical and biotechnology firms have been relying more and more on CDMOs for drug development, manufacturing and packaging, in a bid to cut costs, enhance speed of product launch and concentrate on research activities. This will help them gain from specific technologies, flexible production and expertise in regulations without having to make big investments in manufacturing operations.
2. Growing Demand for Biologics and Biosimilar Manufacturing Services
The exponential rise in biologics, monoclonal antibodies, recombinant proteins, and biosimilar drugs is generating an urgent need for the development of advanced CDMO manufacturing facilities. Since biologics need more advanced technologies to manufacture them, pharmaceutical firms are collaborating with CDMOs that are proficient in manufacturing biologics at a larger scale.
3. Expansion of Cell and Gene Therapy CDMO Capabilities
Commercialization of cell and gene-based treatments has become one of the primary reasons behind investments made by CDMOs in manufacturing technologies that will be able to cater to the production of sophisticated therapeutics. The development of capabilities for viral vectors, plasmids, and cells has been one of the key strategies adopted by companies to serve their customers.
4. Rising Adoption of Continuous Manufacturing Technologies
Continuous manufacturing has gained ground in pharmaceutical production since it makes processes more efficient, consistent, and cost-effective. Automated processes for continuous manufacturing have been adopted by contract development and manufacturing organizations (CDMOs), where production takes less time and is less wasteful than batch manufacturing.
5. Growing Investment in High-Potency API (HPAPI) Manufacturing
The rapid increase in the development of oncology drugs and targeted therapies is driving the demand for high-potent API manufacturing services. CDMOs are equipping themselves with sophisticated containment technology, dedicated manufacturing facilities, and unique safety systems to manufacture potent APIs and stay compliant with all regulations.
6. Expansion of Fill-Finish Manufacturing Services
The demand for sterile fill and finish operations is on the rise owing to the rising manufacture of injectable biologic drugs, vaccines, biosimilars, and advanced therapies. CDMOs are investing heavily in aseptic filling, lyophilization, cartridge manufacturing, vial manufacturing, and pre-filled syringe manufacturing in order to provide comprehensive drug manufacturing services to pharmaceutical organizations.
Top 25 Companies Leading the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
Customize the exclusive Pharmaceutical CDMO Market report today to receive tailored insights, country-specific analysis, and business-focused market intelligence.
1. Lonza Group AG
Lonza Group AG is a worldwide pharmaceutical CDMO that provides development, manufacturing, and commercialization services of biologics, small molecules, and advanced therapies.
Founded: 1897 | Headquarters: Basel, Switzerland
Why It Ranks: One of the biggest and diverse pharmaceutical CDMOs in the world with the highest biologics and advanced therapies expertise.
Regional Dominance: Strong presence in Europe, North America, and Asia-Pacific regions.
Product Line: Biologics manufacturing, cell and gene therapy services, API manufacturing, capsules, and drug product manufacturing.
Recent Development: In 2026, Lonza enhanced its Global Capability Centre in Hyderabad, India, for its worldwide CDMO activities.
2. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific provides global CDMO services for pharmaceutical development, manufacturing, analysis, and laboratory services.
Founded: 2006 | Headquarters: Waltham, Massachusetts, USA
Why It Ranks: Global leader offering integrated end-to-end CDMO services.
Regional Dominance: North America, Europe, and Asia-Pacific.
Product Line: Biologics manufacturing, sterile fill finish, API manufacturing, clinical trial services, and analysis.
Recent Development: In 2025, Thermo Fisher Scientific acquired Sanofi’s Ridgefield facility to add to its network of pharmaceutical manufacturing.
3. Catalent, Inc.
Catalent offers top-notch drug development, biologics manufacturing, drug delivery solutions, and clinical supply services to pharmaceutical and biotech firms.
Founded: 2007 | Headquarters: Somerset, New Jersey, USA
Why It Ranks: One of the foremost companies offering drug delivery and CDMO services in the world.
Regional Dominance: High penetration in North America, Europe, and Asia Pacific regions.
Product Line: Oral drug delivery, biologics manufacturing, gene therapy services, softgel technology, and clinical supplies.
Recent Development: Catalent expanded its biologics and cell & gene therapy manufacturing capabilities in 2025 at multiple locations around the globe.
4. Samsung Biologics Co., Ltd.
Samsung Biologics is among the most renowned and prominent global CDMOs that focus on manufacturing of large-scale biologics.
Founded: 2011 | Headquarters: Incheon, South Korea
Why It Ranks: One of the largest biologics manufacturing capacities in the world.
Regional Dominance: Asia-Pacific and extending operations into North America and Europe.
Product Line: Monoclonal antibodies, biosimilar products, cell culture development, biologics manufacturing, and fill-finish services.
Recent Development: In 2025, Samsung Biologics increased biologics manufacturing capacity with new plants.
5. WuXi AppTec Co., Ltd.
WuXi AppTec offers drug research and development, testing, manufacturing, and commercialization solutions to life science companies worldwide.
Founded: 2000 | Headquarters: Shanghai, China
Why It Ranks: One of the leading integrated pharmaceutical outsourcing firms offering wide range of service capabilities.
Regional Dominance: Asia-Pacific and North America and Europe to some extent.
Product Line: Drug discovery, API manufacture, analytical testing, clinical development, and lab services.
Recent Development: In 2025, WuXi AppTec launched integrated pharmaceutical research and manufacturing services globally.
6. WuXi Biologics
WuXi Biologics is an international biologics contract development and manufacturing organization.
Founded: 2010 | Headquarters: Wuxi, China
Why It Ranks: Global leader in offering biologics development and manufacturing solutions.
Regional Dominance: Asia-Pacific, Europe, and North America.
Product Line: Monoclonal antibodies, recombinant proteins, biosimilars, vaccines, and biologics manufacturing.
Recent Development: In 2025, WuXi Biologics enhanced its biologics manufacturing capacity by opening new manufacturing facilities worldwide.
7. Recipharm AB
Recipharm AB is an international pharmaceutical CDMO offering formulation, manufacturing, and packaging services to pharmaceutical firms.
Founded: 1995 | Headquarters: Stockholm, Sweden
Why It Ranks: Large European CDMO with extensive manufacturing know-how.
Regional Dominance: Europe, with increasing operations in North America and Asia Pacific regions.
Product Line: Oral solid dosage formulations, sterile manufacturing, inhalation products, biologics, and pharmaceutical packaging.
Recent Development: In 2025, Recipharm extended its sterile manufacturing facility for injectable pharmaceutical products.
8. Siegfried Holding AG
Siegfried Holding AG is a leading contract development and manufacturing organization providing API and final formulation development and manufacturing services.
Founded: 1873 | Headquarters: Zofingen, Switzerland
Why It Ranks: Long-standing experience in CDMO services and specialization in APIs and final formulations.
Regional Dominance: Europe, North America, and Asia-Pacific.
Product Line: APIs, oral dosage forms, sterile formulations, and analytical solutions.
Recent Development: In 2025, Siegfried increased the API manufacturing capacity to cater to the rising demand for pharmaceutical outsourcing.
9. Boehringer Ingelheim BioXcellence
Biologics and biopharmaceutical contract development and manufacturing services offered by Boehringer Ingelheim BioXcellence.
Founded: 1885 | Headquarters: Ingelheim am Rhein, Germany
Why It Ranks: World-renowned for excellence in biologics manufacturing.
Regional Dominance: Dominant in Europe, North America, and the Asia Pacific.
Product Line: Biologics development, manufacture of monoclonal antibodies, process development, and biologics manufacturing.
Recent Development: In 2025, BioXcellence extended their biologics manufacturing services due to increasing customer demands.
10. Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies is a multinational CDMO that focuses on the manufacturing of biologics, vaccines, gene therapies, and recombinant proteins.
Founded: 2011 | Headquarters: Teesside, United Kingdom
Why It Ranks: A leading multinational CDMO company that offers manufacturing services for biologics and gene therapies.
Regional Dominance: Europe, North America, and Asia-Pacific.
Product Line: Biologics manufacturing, vaccines, gene therapies, microbial fermentation, and cell culture.
Recent Development: In 2025, Fujifilm Diosynth increased large-scale biologics manufacturing capacity globally.
Schedule a meeting with our market experts to discuss the exclusive Pharmaceutical CDMO Market report and identify the best research solution for your organization.
Conclusion
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is projected to experience impressive growth in the coming years, on account of outsourcing of drug development and manufacturing, increased need for biologics, biosimilars, and cell & gene therapies, and requirement for cost-effective manufacturing. Ongoing innovations in the field of pharmaceutical manufacturing technology, increased clinical pipelines, and investments made in high-potency APIs, sterile fill-finish services, and personalized medicine have also helped in boosting the market growth. Prominent players like Lonza Group AG, Thermo Fisher Scientific Inc., Catalent, Inc., Samsung Biologics Co., Ltd., WuXi AppTec Co., Ltd., WuXi Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim BioXcellence, and Fujifilm Diosynth Biotechnologies are continuing to improve their market presence via capacity expansions, mergers, acquisitions, and investments in advanced manufacturing platforms. With the increase in pharmaceutical innovations and the significance of outsourcing in global drug development activities, the Pharmaceutical CDMO Market is poised for impressive growth in the years to come.
Send us a brief description of your challenge and we'll get back to you within 24 hours.
inquiry@transpireinsight.com
APAC:+91 7666513636
Address
